Review Cancer treatment reviews. 2021 May:96:102179. doi: 10.1016/j.ctrv.2021.102179 Q110.52025

Immunotherapy in non-small cell lung cancer harbouring driver mutations

驱动基因突变非小细胞肺癌的免疫治疗翻译改进

Alfredo Addeo¹, Antonio Passaro², Umberto Malapelle³, Giuseppe Luigi Banna⁴, Vivek Subbiah⁵, Alex Friedlaender⁶

作者单位 +展开

作者单位

¹ Oncology Department, University Hospital, Geneva, Switzerland. Electronic address: alfredo.addeo@hcuge.ch.

² Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy.

³ Department of Haematology/Oncology, Queen Alexandra Hospital, Portsmouth, United Kingdom.

⁴ Department of Public Health, University of Naples Federico II, Naples, Italy.

⁵ Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

⁶ Oncology Department, University Hospital, Geneva, Switzerland.

DOI: 10.1016/j.ctrv.2021.102179 PMID: 33798954

摘要中英对照阅读

点击完成人机验证后继续浏览

相关内容

期刊名：Cancer treatment reviews

缩写：CANCER TREAT REV

ISSN：0305-7372

e-ISSN：1532-1967

IF/分区：10.5/Q1

文章目录更多期刊信息

全文链接

官方链接

PMC全文

引文链接

复制

已复制！

格式：

Immunotherapy in non-small cell lung cancer harbouring driver mutations

驱动基因突变非小细胞肺癌的免疫治疗翻译改进

To be, or not to be: the dilemma of immunotherapy for non-small cell lung cancer harboring various driver mutations

是与否：不同驱动基因突变型非小细胞肺癌的免疫治疗困境

Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer Lacking Driver Mutations and Future Perspectives

驱动基因阴性的晚期非小细胞肺癌患者的免疫治疗及未来展望

[Chinese expert consensus on immunotherapy for advanced non-small lung cancer with oncogenic driver mutations (2022 edition)]

中国肺癌基因突变阴性晚期患者免疫治疗专家共识（2022版）

[Chinese expert consensus on immunotherapy for advanced non-small lung cancer with oncogenic driver mutations (2023 edition)]

《中国驱动基因阳性晚期非小细胞肺癌免疫治疗专家共识（2023版）》

New driver mutations in non-small-cell lung cancer

非小细胞肺癌中的新驱动基因突变

The impact of oncogenic driver mutations on neoadjuvant immunotherapy outcomes in patients with resectable non-small cell lung cancer

驱动突变对可切除性非小细胞肺癌新辅助免疫治疗效果的影响

Targeted Therapy and Immunotherapy Lead to Rapid Regression of Advanced Non-Small Cell Lung Cancer with Multiple Driver Mutations

针对多重驱动基因突变的晚期非小细胞肺癌进行靶向治疗和免疫治疗可使肿瘤迅速退缩

Oncogenic driver mutations in non-small cell lung cancer: Past, present and future

非小细胞肺癌驱动基因突变的研究：过去、现在和未来

Immunotherapy in non-small cell lung cancer harbouring driver mutations

驱动基因突变非小细胞肺癌的免疫治疗 翻译改进

To be, or not to be: the dilemma of immunotherapy for non-small cell lung cancer harboring various driver mutations

是与否：不同驱动基因突变型非小细胞肺癌的免疫治疗困境

Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer Lacking Driver Mutations and Future Perspectives

驱动基因阴性的晚期非小细胞肺癌患者的免疫治疗及未来展望

[Chinese expert consensus on immunotherapy for advanced non-small lung cancer with oncogenic driver mutations (2022 edition)]

中国肺癌基因突变阴性晚期患者免疫治疗专家共识（2022版）

[Chinese expert consensus on immunotherapy for advanced non-small lung cancer with oncogenic driver mutations (2023 edition)]

《中国驱动基因阳性晚期非小细胞肺癌免疫治疗专家共识（2023版）》

New driver mutations in non-small-cell lung cancer

非小细胞肺癌中的新驱动基因突变

The impact of oncogenic driver mutations on neoadjuvant immunotherapy outcomes in patients with resectable non-small cell lung cancer

驱动突变对可切除性非小细胞肺癌新辅助免疫治疗效果的影响

Targeted Therapy and Immunotherapy Lead to Rapid Regression of Advanced Non-Small Cell Lung Cancer with Multiple Driver Mutations

针对多重驱动基因突变的晚期非小细胞肺癌进行靶向治疗和免疫治疗可使肿瘤迅速退缩

Oncogenic driver mutations in non-small cell lung cancer: Past, present and future

非小细胞肺癌驱动基因突变的研究：过去、现在和未来

驱动基因突变非小细胞肺癌的免疫治疗翻译改进